GDF-15作为整合性心血管代谢生物标志物
本文为临床化学叙述性综述,阐述GDF-15作为整合性生物标志物的病理生理基础与临床应用。GDF-15在心肌细胞、脂肪组织等多种细胞表达,响应组织损伤、炎症和代谢应激而升高,与2型糖尿病、肥胖、高血压、动脉粥样硬化、心衰和慢性肾病相关。其升高与心血管事件、肾衰竭和死亡等不良结局相关,但预后切点在不同研究、人群和检测平台间存在差异,需谨慎对待。
要点
- GDF-15是应激诱导的整合性生物标志物,反映代谢应激、炎症和组织损伤。
- 在糖尿病、肥胖、高血压、心衰和动脉粥样硬化中,GDF-15升高与不良结局相关。
- 检测方法以免疫分析为主,质谱新技术在开发中;检测间变异和标准化是临床应用的主要障碍。
核心结论
- GDF-15是心血管代谢疾病中代谢应激、炎症和组织损伤的强效整合性生物标志物。
- 其临床应用可能有助于早期风险分层、个体化治疗和监测疾病进展。
研究设计与样本
- 临床化学叙述性综述,未报告系统检索范围或样本量。
主要发现
- GDF-15在心肌细胞、脂肪组织、巨噬细胞、内皮细胞和血管平滑肌细胞中丰富表达。
- GDF-15水平响应组织损伤、炎症和代谢应激而升高,在2型糖尿病、肥胖、高血压、动脉粥样硬化、心衰和慢性肾病中升高。
- GDF-15升高与糖尿病、肥胖、高血压、心衰和动脉粥样硬化中的不良结局(如心血管事件、肾衰竭和死亡)一致相关。
- GDF-15的生物学变异决定因素包括年龄、性别、肾功能、遗传变异和合并症,影响参考区间和纵向解读。
- 检测间变异和检测标准化被认为是临床应用的主要障碍。
关键数值与推荐
- 预后切点在不同研究、人群和检测平台间提出不一,应谨慎对待,直至获得协调检测和经前瞻性研究临床验证的决策限。
- 未来研究应聚焦于优化检测标准化、建立循证参考区间(及参考变化值)和阐明临床实用决策限及GDF-15通路治疗意义。
临床怎么用
- GDF-15检测以免疫分析为主,质谱新技术在开发中。
- 解读GDF-15结果时需考虑年龄、性别、肾功能、遗传变异和合并症对参考区间和纵向变化的影响。
- 应谨慎使用现有预后切点,因不同研究、人群和检测平台间存在差异。
局限性
- 检测间变异和检测标准化是临床应用的主要障碍。
- 预后切点在不同研究、人群和测量平台间提出不一,需协调检测和前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Growth Differentiation Factor 15 (GDF-15) is a stress-inducible cytokine that is abundantly expressed in cardiomyocytes, adipose tissue, macrophages, endothelial cells, and vascular smooth muscle cells. The levels of this biomarker increase in response to tissue injury, inflammation, and metabolic stress and are elevated in the presence of primary cardiometabolic diseases, such as type 2 diabetes, obesity, hypertension, atherosclerosis, heart failure, and chronic kidney disease. This is articulated in a clinical chemistry narrative review, which elucidates why GDF-15 can be characterized as an integrative biomarker. This characterization is due to the shared pathophysiological processes of metabolic stress, inflammation, oxidative/mitochondrial stress, and tissue injury across these conditions, as well as its clinical applications in risk assessment, prognosis, and monitoring. We also briefly present modern methods to measure circulating GDF-15 (primarily immunoassays, with new mass-spectrometry techniques being developed) and note that inter-assay variability and assay standardization are considered to be the major impediments to clinical application. The most significant determinants of biological variability (age, sex, renal function, genetic variation, and comorbidities), by which reference intervals and longitudinal interpretation are affected, are also highlighted. Increased GDF-15 is consistently associated with poor outcomes in diabetes, obesity, hypertension, heart failure, and atherosclerosis, such as cardiovascular events, kidney failure, and death. Nonetheless, prognostic cutoffs have been proposed variably across studies, populations, and measurement platforms. Therefore, these thresholds should be approached with caution until harmonized assays and clinically validated decision limits established through prospective studies are available. GDF-15 is a powerful integrative biomarker of metabolic stress, inflammation, and tissue injury in cardiometabolic diseases. Its introduction into clinical practice may enhance early risk stratification, personalize therapeutic interventions and monitor disease progression. Future studies should focus on optimizing the standardization of assays, developing evidence-based reference intervals (and reference change values), and elucidating clinically practical decision limits and therapeutic implications of the GDF-15 pathway in the treatment of cardiometabolic diseases.
引用
- Afzal O, Afzal M, Khan NH, et al. GDF-15 as an integrative cardiometabolic biomarker. Clin Chim Acta. 2026. PMID: 41539642. doi:10.1016/j.cca.2026.120839
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。